Johnson & Johnson's US$1bn Investment for Vision & Eye Care

Johnson & Johnson has announced a major investment of more than US$1bn to strengthen its Vision business and expand US-based manufacturing, packaging and distribution capabilities.

The initiative is designed to support growing demand while enhancing supply chain resilience and operational efficiency.

The investment underscores the healthcare giant’s commitment to advancing eye health innovation and improving access to high-quality vision care solutions for millions of patients worldwide.

Expanding manufacturing for eye care demand

Johnson & Johnson’s investment will expand its Vision operations by constructing a new state-of-the-art distribution facility and implementing advanced manufacturing and packaging technologies.

These upgrades are intended to increase production capacity for ACUVUE contact lenses, one of the most recognised brands in vision care.

As demand for contact lenses continues to grow, the company aims to ensure a reliable supply of products for patients across the United States and international markets.

“This investment reinforces our long-standing conviction that advanced manufacturing in the United States is essential to delivering innovative, high quality healthcare solutions to patients at home and around the world,” says Joaquin Duato, Chairman and CEO of Johnson & Johnson.

“By further strengthening our Vision operations in Jacksonville with next-generation manufacturing, packaging and distribution capabilities, we are enhancing the resilience of our US supply chain while helping more people see better and live better.

"This commitment reflects the confidence we have in our people, our technology and our more than 40-year legacy of advancing eye health globally.”

By investing in next-generation technologies, Johnson & Johnson is positioning itself to better serve the evolving needs of eye care consumers and healthcare professionals.

Strengthening healthcare supply chains

The Jacksonville expansion reflects Johnson & Johnson’s broader strategy to reinforce domestic healthcare manufacturing and distribution infrastructure.

Company leadership emphasised that advanced manufacturing in the US plays a critical role in delivering innovative, high-quality healthcare solutions for patients.

The investment forms part of Johnson & Johnson’s previously announced US$55bn commitment to US manufacturing, research and development and technology through early 2029.

Construction of the new facility is already underway, with full operations expected to begin in 2028.

“Johnson & Johnson’s commitment is a strong vote of confidence in Jacksonville, our workforce and our future,” says Mayor Donna Deegan.

“Jacksonville continues to lead in advanced manufacturing and life sciences innovation. This expansion strengthens our high-tech footprint while creating quality jobs and long-term opportunities for our community.”  

By increasing local production and distribution capacity, the company hopes to strengthen supply chain resilience while ensuring greater access to essential vision care products.

Building a vision healthcare legacy

Johnson & Johnson has maintained a presence in Jacksonville since 1981 and has become a significant contributor to both the local economy and the healthcare industry.

The company currently manufactures more than 1.7 billion ACUVUE contact lenses annually for US patients and supports approximately 3,500 employees in the region.

Its operations span more than 1.5 million square feet of manufacturing, research, distribution and operational facilities. Local leaders view the expansion as a strong endorsement of Jacksonville’s growing reputation as a hub for advanced manufacturing and life sciences innovation.

Beyond economic benefits, the investment reinforces Johnson & Johnson’s longstanding mission to improve eye health outcomes and help millions of people achieve better vision and quality of life.